About Collegium Pharma
Collegium Pharma is a company based in Canton (United States) founded in 2002 by Michael Heffernan. Collegium Pharma has raised $103 million across 8 funding rounds from investors including TPG, HHS and RA Capital. The company has 357 employees as of December 31, 2024. Collegium Pharma has completed 2 acquisitions, including BioDelivery Sciences International and Ironshore Pharmaceuticals. Collegium Pharma offers products and services including Differentiated Medications. Collegium Pharma operates in a competitive market with competitors including Flexion Therapeutics, Cara Therapeutics, Eliem Therapeutics, Ethypharm and Zogenix, among others.
- Headquarter Canton, United States
- Employees 357 as on 31 Dec, 2024
- Founders Michael Heffernan
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Collegium Pharmaceutical, Inc.
-
Annual Revenue
$631.45 M (USD)11.41as on Dec 31, 2024
-
Net Profit
$69.19 M (USD)43.68as on Dec 31, 2024
-
EBITDA
$360.47 M (USD)11.01as on Dec 31, 2024
-
Total Equity Funding
$103 M (USD)
in 8 rounds
-
Latest Funding Round
$20 M (USD), Post-IPO
Nov 08, 2018
-
Investors
TPG
& 9 more
-
Employee Count
357
as on Dec 31, 2024
-
Investments & Acquisitions
BioDelivery Sciences International
& 1 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Collegium Pharma
Collegium Pharma is a publicly listed company on the NASDAQ with ticker symbol COLL in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Collegium Pharma
Collegium Pharma offers a comprehensive portfolio of products and services, including Differentiated Medications.
Medications addressing serious medical conditions through scientific innovation.
People of Collegium Pharma
Unlock access to complete
Unlock access to complete
Funding Insights of Collegium Pharma
Collegium Pharma has successfully raised a total of $103M across 8 strategic funding rounds. The most recent funding activity was a Post-IPO round of $20 million completed in November 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Collegium Pharma
Collegium Pharma has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include TPG, HHS and RA Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Fund of funds focused on pre-seed and seed-stage companies
|
Locked | Locked | Locked | |
|
Early-stage and late-stage biotech and finance companies are funded.
|
Locked | Locked | Locked | |
|
Private equity firm focused on life science sector
|
Locked | Locked | Locked |
Investor details for Collegium Pharma
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Collegium Pharma
Collegium Pharma has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include BioDelivery Sciences International and Ironshore Pharmaceuticals.
Investment portfolio details for Collegium Pharma
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Drug delivery technology and ADHD therapeutics are developed.
|
Locked | Locked | 2008 | Locked | |
|
Specialty pharmaceutical solutions are developed for pain management and addiction.
|
Locked | Locked | 1997 | Locked |
Complete acquisition details for Collegium Pharma
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Collegium Pharma
Detailed financials for Collegium Pharma
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Collegium Pharma Comparisons
Peer comparison for Collegium Pharma
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Collegium Pharma
Collegium Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Flexion Therapeutics, Cara Therapeutics, Eliem Therapeutics, Ethypharm and Zogenix, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of therapies for the treatment of musculoskeletal disorders
|
|
| Locked | Locked | Locked |
Developer of therapeutics for pain relief and inflammatory diseases
|
|
| Locked | Locked | Locked |
Develops antibody-based treatments for autoimmune and inflammatory disorders.
|
|
| Locked | Locked | Locked |
Therapies for pain and addiction treatment are developed.
|
|
| Locked | Locked | Locked |
Drug delivery systems for CNS disorders and pain are developed.
|
|
| Locked | Locked | Locked |
Reformulated injectables for chemotherapy side effects and pain are developed.
|
Detailed competitors of Collegium Pharma
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Collegium Pharma
Complete news archive for Collegium Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Collegium Pharma
Collegium Pharma was founded in 2002 and raised its 1st funding round 4 years after it was founded.
Collegium Pharma is headquartered in Canton, United States. It is registered at Canton, Ohio, United States.
Michael Heffernan is the current CEO of Collegium Pharma. They have also founded this company.
Collegium Pharma is a funded company, having raised a total of $103M across 8 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Collegium Pharma is 357.
Annual revenue of Collegium Pharma is $631.45M as on Dec 31, 2024.
Therapeutics for chronic pain management are developed by Collegium Pharmaceutical, which was founded in 2002 and is based in Canton, United States. The proprietary DETERx platform is used to combine active ingredients with fatty acids and waxes, forming microsphere capsules with extended-release and abuse-deterrent features. Xtampza ER serves as the flagship product, delivering extended-release oxycodone. Formulations for oxymorphone, hydrocodone, morphine, and methylphenidate are also produced.
Collegium Pharma's top competitors include Flexion Therapeutics, Cara Therapeutics and Trevena.
Collegium Pharma offers Differentiated Medications.
Yes, Collegium Pharma is publicly traded on NASDAQ under the ticker symbol COLL.
Collegium Pharma has made 2 acquisitions, including BioDelivery Sciences International, and Ironshore Pharmaceuticals.
Collegium Pharma has 10 investors. Key investors include TPG, HHS, RA Capital, Frazier Healthcare Partners, and Westfield Capital.
The ticker symbol of Collegium Pharma is COLL on NASDAQ.